Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yuan-Yuan Liang, Cheng-Mei Zhang & Zhao-Peng Liu. (2018) Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors. Expert Opinion on Therapeutic Patents 28:8, pages 647-651.
Read now
Read now
Soham D. Puvvada, Hongli Li, Lisa M. Rimsza, Steven H. Bernstein, Richard I. Fisher, Michael LeBlanc, Monika Schmelz, Betty Glinsmann-Gibson, Thomas P. Miller, Anne-Marie Maddox, Jonathan W. Friedberg, Sonali M. Smith & Daniel O. Persky. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leukemia & Lymphoma 57:10, pages 2359-2369.
Read now
Read now
Geneviève P Delcuve, Dilshad H Khan & James R Davie. (2013) Targeting class I histone deacetylases in cancer therapy. Expert Opinion on Therapeutic Targets 17:1, pages 29-41.
Read now
Read now
Articles from other publishers (84)
Rourou Li, Yujia Tian, Zhenwu Yang, Yueshan Ji, Jiaqi Ding & Aixia Yan. (2022) Classification models and SAR analysis on HDAC1 inhibitors using machine learning methods. Molecular Diversity 27:3, pages 1037-1051.
Crossref
Crossref
Melissa L. Johnson, James Strauss, Manish R. Patel, Edward B. Garon, Keith D. Eaton, Tavette Neskorik, Josée Morin, Richard Chao & Balazs Halmos. (2023) Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study. Clinical Lung Cancer 24:3, pages 218-227.
Crossref
Crossref
Bi Lian, Xiaosong Chen & Kunwei Shen. (2023) Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. Frontiers in Immunology 14.
Crossref
Crossref
Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, Veena Vijayan, Deepak Kumar, Jashwanth Naik, Suresh Thareja, Jagat Pal Yadav, Prateek Pathak, Maria Grishina, Amita Verma, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas & Pradeep Kumar. (2023) Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. Pharmaceuticals 16:2, pages 299.
Crossref
Crossref
Marcelo Lima Ribeiro, Salvador Sánchez Vinces, Laura Mondragon & Gael Roué. (2023) Epigenetic targets in B- and T-cell lymphomas: latest developments. Therapeutic Advances in Hematology 14, pages 204062072311734.
Crossref
Crossref
Shabir Ahmad Ganai, Basit Amin Shah & Manzoor Ahmad Yatoo. 2023. Epigenetic Regulation of Cancer in Response to Chemotherapy. Epigenetic Regulation of Cancer in Response to Chemotherapy
163
198
.
N. Jeelan Basha & S. M. Basavarajaiah. (2022) An insight into therapeutic efficacy of heterocycles as histone‐modifying enzyme inhibitors that targets cancer epigenetic pathways. Chemical Biology & Drug Design 100:5, pages 682-698.
Crossref
Crossref
Jeffrey S. Weber, Benjamin A. Levinson, Andressa S. Laino, Anna C. Pavlick & David M. Woods. (2022) Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Research 32:5, pages 324-333.
Crossref
Crossref
Jingru Yang, Cong Song & Xianquan Zhan. (2022) The role of protein acetylation in carcinogenesis and targeted drug discovery. Frontiers in Endocrinology 13.
Crossref
Crossref
Anthony Twumasi BoatengAraba Abaidoo-MylesEvelyn Yayra BonneyGeorge B. Kyei. (2022) Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal. AIDS Research and Human Retroviruses 38:8, pages 615-621.
Crossref
Crossref
Dusan Ruzic, Nemanja Djoković, Tatjana Srdić-Rajić, Cesar Echeverria, Katarina Nikolic & Juan F. Santibanez. (2022) Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics 14:1, pages 209.
Crossref
Crossref
Zixue Zhang, Qingwei Zhang, Hao Zhang, Minru Jiao, Zheng Guo, Xinyan Peng, Lei Fu & Jianqi Li. (2021) Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities. Bioorganic Chemistry 117, pages 105407.
Crossref
Crossref
Jun Lu, Xiang He, Lijuan Zhang, Ran Zhang & Wenzheng Li. (2021) Acetylation in Tumor Immune Evasion Regulation. Frontiers in Pharmacology 12.
Crossref
Crossref
Farkhondeh Khanjani, Leila Jafari, Somayeh Azadiyan, Sahar Roozbehi, Cobra Moradian, Javad Zahiri, Sadegh Hasannia & Reza H. Sajedi. (2021) Drug repositioning based on gene expression data for human HER2-positive breast cancer. Archives of Biochemistry and Biophysics 712, pages 109043.
Crossref
Crossref
Alvina I. Khamidullina, Ekaterina A. Varlamova, Nour Alhuda Hammoud, Margarita A. Yastrebova & Alexandra V. Bruter. (2021) Gene Transcription as a Therapeutic Target in Leukemia. International Journal of Molecular Sciences 22:14, pages 7340.
Crossref
Crossref
Mohammed Ghiboub, Ahmed M. I. Elfiky, Menno P. J. de Winther, Nicola R. Harker, David F. Tough & Wouter J. de Jonge. (2021) Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives. Journal of Personalized Medicine 11:5, pages 336.
Crossref
Crossref
Francesca Cavallo, Flavia Troglio, Giovanni Fagà, Daniele Fancelli, Reinald Shyti, Sebastiano Trattaro, Matteo Zanella, Giuseppe D’Agostino, James M. Hughes, Maria Rosaria Cera, Maurizio Pasi, Michele Gabriele, Maddalena Lazzarin, Marija Mihailovich, Frank Kooy, Alessandro Rosa, Ciro Mercurio, Mario Varasi & Giuseppe Testa. (2020) High-throughput screening identifies histone deacetylase inhibitors that modulate GTF2I expression in 7q11.23 microduplication autism spectrum disorder patient-derived cortical neurons. Molecular Autism 11:1.
Crossref
Crossref
Pan Wang, Zi Wang & Jing Liu. (2020) Role of HDACs in normal and malignant hematopoiesis. Molecular Cancer 19:1.
Crossref
Crossref
I-Chung Chen, Bidyadhar Sethy & Jing-Ping Liou. (2020) Recent Update of HDAC Inhibitors in Lymphoma. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Hanna Jung, Eunjo Lee, Inkyeom Kim & Gun Jik Kim. (2020) Histone Deacetylase Inhibition Attenuates Aortic Remodeling in Rats under Pressure Overload. BioMed Research International 2020, pages 1-8.
Crossref
Crossref
Mengqing Deng, Shuo Yang, Yue Ji, Yan Lu, Ming Qiu, Yanhui Sheng, Wei Sun & Xiangqing Kong. (2020) Overexpression of peptidase inhibitor 16 attenuates angiotensin II–induced cardiac fibrosis via regulating HDAC1 of cardiac fibroblasts. Journal of Cellular and Molecular Medicine 24:9, pages 5249-5259.
Crossref
Crossref
Zohaib Rana, Sarah Diermeier, Muhammad Hanif & Rhonda J. Rosengren. (2020) Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer. Biomedicines 8:2, pages 22.
Crossref
Crossref
Zhihua Shen, Xiaomin Liao, Zhongming Shao, Muyin Feng, Jianling Yuan, Sisi Wang, Siyuan Gan, Yanping Ha, Zhiwei He & Wei Jie. (2019) Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability. BMC Cancer 19:1.
Crossref
Crossref
Maria Mrakovcic & Leopold F. Fröhlich. 2019. Genes and Cancer. Genes and Cancer.
Li-Ming Zhao & Jie-Huan Zhang. (2019) Histone Deacetylase Inhibitors in Tumor Immunotherapy. Current Medicinal Chemistry 26:17, pages 2990-3008.
Crossref
Crossref
Veronika A. Myasoedova, Vasily Sukhorukov, Andrey V. Grechko, Dongwei Zhang, Elena Romanenko, Vawain Orekhov & Alexander N. Orekhov. (2019) Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. Current Pharmaceutical Design 25:6, pages 635-641.
Crossref
Crossref
Stefania Crisci, Raffaele Di Francia, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Rosaria De Filippi, Massimiliano Berretta, Paola Rossi & Antonio Pinto. (2019) Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Frontiers in Oncology 9.
Crossref
Crossref
Maria Mrakovcic, Johannes Kleinheinz & Leopold F. Fröhlich. (2019) p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. International Journal of Molecular Sciences 20:10, pages 2415.
Crossref
Crossref
Debarati Banik, Sara Moufarrij & Alejandro Villagra. (2019) Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. International Journal of Molecular Sciences 20:9, pages 2241.
Crossref
Crossref
Samir El-Rayes, Gomaa M. S., Abouelmagd A., Walid Fathalla & Ibrahim. A. I. Ali. (2019) Synthesis and antiproliferative assay of triazolyl-2,2-dimethyl-3-phenylpropanoates as potential HDAC inhibitors. RSC Advances 9:24, pages 13896-13907.
Crossref
Crossref
He Miao, Jianjun Gao, Zishuo Mou, Baolei Wang, Li Zhang, Li Su, Yantao Han & Yepeng Luan. (2019) Design, synthesis and biological evaluation of 4-piperidin-4-yl-triazole derivatives as novel histone deacetylase inhibitors. BioScience Trends 13:2, pages 197-203.
Crossref
Crossref
Kirill Gorshkov, Ni Sima, Wei Sun, Billy Lu, Wei Huang, Jameson Travers, Carleen Klumpp-Thomas, Samuel G. Michael, Tuan Xu, Ruili Huang, Emily M. Lee, Xiaodong Cheng & Wei Zheng. (2019) Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds. Translational Oncology 12:3, pages 441-452.
Crossref
Crossref
Petros Grivas, Amir Mortazavi, Joel Picus, Noah M. Hahn, Matthew I. Milowsky, Lowell L. Hart, Ajjai Alva, Joaquim Bellmunt, Sumanta K. Pal, Richard M. Bambury, Peter H. O’Donnell, Sumati Gupta, Elizabeth A. Guancial, Guru P. Sonpavde, Demiana Faltaos, Diane Potvin, James G. Christensen, Richard C. Chao & Jonathan E. Rosenberg. (2018) Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer 125:4, pages 533-540.
Crossref
Crossref
Hei-Jen Huang, Hsin-Yu Huang & Hsiu Mei Hsieh-Li. (2019)
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ
25-35
-induced anxiety and cognitive deficits in a mouse model
. CNS Neuroscience & Therapeutics 25:2, pages 175-186.
Crossref
Crossref
Rashmi R. Shah. (2019) Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology. Drug Safety 42:2, pages 235-245.
Crossref
Crossref
Maria Mrakovcic, Lauren Bohner, Marcel Hanisch & Leopold F. Fröhlich. (2018) Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. International Journal of Molecular Sciences 19:12, pages 3952.
Crossref
Crossref
Rui Deng, Peng Zhang, Weizhen Liu, Xiangyu Zeng, Xianxiong Ma, Liang Shi, Tao Wang, Yuping Yin, Weilong Chang, Pei Zhang, Guobin Wang & Kaixiong Tao. (2018) HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer. Clinical Epigenetics 10:1.
Crossref
Crossref
David A Pride & Alyssa R Summers. (2018) The emergence of specific HDAC inhibitors and their clinical efficacy in the treatment of hematologic malignancies and breast cancer. International Journal of Molecular Biology 3:5.
Crossref
Crossref
Emily Chan, E. Gabriela Chiorean, Peter J. O’Dwyer, Nashat Y. Gabrail, Thierry Alcindor, Diane Potvin, Richard Chao & Herbert Hurwitz. (2017) Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemotherapy and Pharmacology 81:2, pages 355-364.
Crossref
Crossref
Xuan Wang, Xiaoye Jiang, Shiyou Sun & Yongqiong Liu. (2018) Synthesis and biological evaluation of novel quinolone derivatives dual targeting histone deacetylase and tubulin polymerization as antiproliferative agents. RSC Advances 8:30, pages 16494-16502.
Crossref
Crossref
Hyung Chan Suh & H. Phillip Koeffler. 2018. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood
465
482
.
Gonzalo Lopez, Danielle Braggio, Abeba Zewdu, Lucia Casadei, Kara Batte, Hemant Kumar Bid, David Koller, Peter Yu, Obiajulu Hans Iwenofu, Anne Strohecker, Edwin Choy, Dina Lev & Raphael Pollock. (2017) Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates. PLOS ONE 12:11, pages e0188859.
Crossref
Crossref
Maria Mrakovcic, Johannes Kleinheinz & Leopold Fröhlich. (2017) Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53. International Journal of Molecular Sciences 18:9, pages 1883.
Crossref
Crossref
Connie L. Batlevi, Michael Crump, Charalambos Andreadis, David Rizzieri, Sarit E. Assouline, Susan Fox, Richard H. C. van der Jagt, Amanda Copeland, Diane Potvin, Richard Chao & Anas Younes. (2017) A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. British Journal of Haematology 178:3, pages 434-441.
Crossref
Crossref
Xiaoyang Li, Yingjie Zhang, Yuqi Jiang, Jingde Wu, Elizabeth S. Inks, C. James Chou, Shuai Gao, Jinning Hou, Qinge Ding, Jingyao Li, Xue Wang, Yongxue Huang & Wenfang Xu. (2017) Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study. European Journal of Medicinal Chemistry 134, pages 185-206.
Crossref
Crossref
Qingwei Zhang, Bingliu Lu & Jianqi Li. (2017) Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors. Bioorganic & Medicinal Chemistry Letters 27:14, pages 3162-3166.
Crossref
Crossref
Mamdouh F.A. Mohamed, Montaser Sh.A. Shaykoon, Mostafa H. Abdelrahman, Bakheet E.M. Elsadek, Ahmed S. Aboraia & Gamal El-Din A.A. Abuo-Rahma. (2017) Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors. Bioorganic Chemistry 72, pages 32-41.
Crossref
Crossref
Subhankar Biswas & C. Mallikarjuna Rao. (2017) Epigenetics in cancer: Fundamentals and Beyond. Pharmacology & Therapeutics 173, pages 118-134.
Crossref
Crossref
Sonia Coni, Anna Barbara Mancuso, Laura Di Magno, Giulia Sdruscia, Simona Manni, Silvia Maria Serrao, Dante Rotili, Eleonora Spiombi, Francesca Bufalieri, Marialaura Petroni, Monika Kusio-Kobialka, Enrico De Smaele, Elisabetta Ferretti, Carlo Capalbo, Antonello Mai, Pawel Niewiadomski, Isabella Screpanti, Lucia Di Marcotullio & Gianluca Canettieri. (2017) Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. Scientific Reports 7:1.
Crossref
Crossref
D. Rajasekhar Reddy, Flavio Ballante, Nancy J. Zhou & Garland R. Marshall. (2017) Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors. European Journal of Medicinal Chemistry 127, pages 531-553.
Crossref
Crossref
Abdullahi İbrahim UBA & Kemal YELEKÇİ. (2017) Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. TURKISH JOURNAL OF BIOLOGY 41, pages 901-918.
Crossref
Crossref
Xiaobin Li, Minghai Tang, Hairong Wang, Liang Ma, Haoyu Ye, Chunyu Wang, Qiunan Yang, Li Wan & Lijuan Chen. (2016) In Vitro and In Vivo Primary Metabolic Characterization of F18, a Novel Histone Deacetylase-6 (HDAC6) Inhibitor, Using UHPLC–QqQ–MS/MS and Q-TOF–MS Methods. Chromatographia 79:21-22, pages 1479-1490.
Crossref
Crossref
Michaela Angelika Ihle, Sabine Merkelbach‐Bruse, Wolfgang Hartmann, Sebastian Bauer, Nancy Ratner, Hiroshi Sonobe, Jun Nishio, Olle Larsson, Pierre Åman, Florence Pedeutour, Takahiro Taguchi, Eva Wardelmann, Reinhard Buettner & Hans‐Ulrich Schildhaus. (2016) HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. The Journal of Pathology: Clinical Research 2:2, pages 59-71.
Crossref
Crossref
Zhuang Yang, Taijin Wang, Fang Wang, Ting Niu, Zhuowei Liu, Xiaoxin Chen, Chaofeng Long, Minghai Tang, Dong Cao, Xiaoyan Wang, Wei Xiang, Yuyao Yi, Liang Ma, Jingsong You & Lijuan Chen. (2015) Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. Journal of Medicinal Chemistry 59:4, pages 1455-1470.
Crossref
Crossref
Victoria El-Khoury & Guy Berchem. 2016. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging
221
240
.
Thea van den Bosch, Niek G.J. Leus, Tirza Timmerman & Frank J. Dekker. 2016. Drug Discovery in Cancer Epigenetics. Drug Discovery in Cancer Epigenetics
191
208
.
Diana Markozashvili, Vincent Ribrag & Yegor S. Vassetzky. (2015) Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies. Investigational New Drugs 33:6, pages 1280-1291.
Crossref
Crossref
Hong-tao Shang, Ji-wei Ding, Shu-ying Yu, Tao Wu, Qiu-li Zhang & Fu-jun Liang. (2015) Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacologica Sinica 36:8, pages 908-916.
Crossref
Crossref
Rosaria BenedettiMariarosaria ConteLucia Altucci. (2015) Targeting Histone Deacetylases in Diseases: Where Are We?. Antioxidants & Redox Signaling 23:1, pages 99-126.
Crossref
Crossref
Eric J. Feldman. (2015) Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014. Clinical Lymphoma Myeloma and Leukemia 15, pages S91-S93.
Crossref
Crossref
Jinzhang Cai, Qingwei Zhang, Kezhi Lin, Lufeng Hu & Yuancai Zheng. (2015) The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method. BioMed Research International 2015, pages 1-7.
Crossref
Crossref
Pierfausto Seneci. 2015. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease
135
172
.
Katherine B. Schuetze, Timothy A. McKinsey & Carlin S. Long. (2014) Targeting cardiac fibroblasts to treat fibrosis of the heart: Focus on HDACs. Journal of Molecular and Cellular Cardiology 70, pages 100-107.
Crossref
Crossref
Xiaoyang Li, Elizabeth S. Inks, Xiaoguang Li, Jinning Hou, C. James Chou, Jian Zhang, Yuqi Jiang, Yingjie Zhang & Wenfang Xu. (2014)
Discovery of the First
N
-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity
. Journal of Medicinal Chemistry 57:8, pages 3324-3341.
Crossref
Crossref
Tao You, Ke Chen, Fei-Hai Wang, Pi-Hong Li, Li-Yi Li, Zhi-Hao Wu, Kong-Hai Ni & Zhi-Qiang Zheng. (2014) Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors. Chinese Chemical Letters 25:3, pages 474-478.
Crossref
Crossref
Sarah M. Williams, Lucy Golden-Mason, Bradley S. Ferguson, Katherine B. Schuetze, Maria A. Cavasin, Kim Demos-Davies, Michael E. Yeager, Kurt R. Stenmark & Timothy A. McKinsey. (2014) Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. Journal of Molecular and Cellular Cardiology 67, pages 112-125.
Crossref
Crossref
Jane J. Sung, Katherine Ververis & Tom C. Karagiannis. (2014) Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. Journal of Photochemistry and Photobiology B: Biology 131, pages 104-112.
Crossref
Crossref
Shiliang Tu, Hang Yuan, Jie Hu, Chengguang Zhao, Rui Chai & Hongfeng Cao. (2014) Design, Synthesis and Biological Evaluation of Nitro Oxide Donating <i>N</i>-Hydroxycinnamamide Derivatives as Histone Deacetylase Inhibitors. Chemical and Pharmaceutical Bulletin 62:12, pages 1185-1191.
Crossref
Crossref
Andreas Brunschweiger & Jonathan Hall. 2013. Medicinal Chemistry Approaches to Personalized Medicine. Medicinal Chemistry Approaches to Personalized Medicine
343
364
.
Chao-Wu Yu, Pei-Teh Chang, Ling-Wei Hsin & Ji-Wang Chern. (2013) Quinazolin-4-one Derivatives as Selective Histone Deacetylase-6 Inhibitors for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry 56:17, pages 6775-6791.
Crossref
Crossref
Jian-Sheng Diao, Wen-Sen Xia, Cheng-Gang Yi, Yang Yang, Xi Zhang, Wei Xia, Mao-Guo Shu, Ying-Mei Wang, Lin Gui & Shu-Zhong Guo. (2013) Histone Deacetylase Inhibitor Reduces Hypertrophic Scarring in a Rabbit Ear Model. Plastic and Reconstructive Surgery 132:1, pages 61e-69e.
Crossref
Crossref
Kotaro Shirakawa, Leonard Chavez, Shweta Hakre, Vincenzo Calvanese & Eric Verdin. (2013) Reactivation of latent HIV by histone deacetylase inhibitors. Trends in Microbiology 21:6, pages 277-285.
Crossref
Crossref
Yukihiro Itoh, Takayoshi Suzuki & Naoki Miyata. (2013) Small-molecular modulators of cancer-associated epigenetic mechanisms. Molecular BioSystems 9:5, pages 873.
Crossref
Crossref
Maria New, Heidi Olzscha & Nicholas B. La Thangue. (2012) HDAC inhibitor-based therapies: Can we interpret the code?. Molecular Oncology 6:6, pages 637-656.
Crossref
Crossref
Carmela Dell'Aversana, Ilaria Lepore & Lucia Altucci. (2012) HDAC modulation and cell death in the clinic. Experimental Cell Research 318:11, pages 1229-1244.
Crossref
Crossref
Sophia N Ononye, Michael van Heyst, Eric M Falcone, Amy C Anderson & Dennis L Wright. (2012) Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharmaceutical Patent Analyst 1:2, pages 207-221.
Crossref
Crossref
Maria A. CavasinKim Demos-DaviesTodd R. HornLori A. WalkerDouglas D. LemonNicholas BirdseyMary C.M. Weiser-EvansJulie HarralDavid C. IrwinAdil AnwarMichael E. YeagerMin LiPeter A. WatsonRaphael A. NemenoffPeter M. ButtrickKurt R. StenmarkTimothy A. McKinsey. (2012) Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism. Circulation Research 110:5, pages 739-748.
Crossref
Crossref
Andreas Brunschweiger & Jonathan Hall. (2012) A Decade of the Human Genome Sequence-How Does the Medicinal Chemist Benefit?. ChemMedChem 7:2, pages 194-203.
Crossref
Crossref
Nessa Carey. (2012) Epigenetics—an emerging and highly promising source of new drug targets. MedChemComm 3:2, pages 162-166.
Crossref
Crossref
Omar Khan & Nicholas B La Thangue. (2011) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunology & Cell Biology 90:1, pages 85-94.
Crossref
Crossref
Christopher Chang. 2012. Epigenetics in Human Disease. Epigenetics in Human Disease
225
251
.
Robert W. Robey, Arup R. Chakraborty, Agnes Basseville, Victoria Luchenko, Julian Bahr, Zhirong Zhan & Susan E. Bates. (2011) Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance. Molecular Pharmaceutics 8:6, pages 2021-2031.
Crossref
Crossref
Im-Soon Lee. (2011) Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies. Biomolecules and Therapeutics 19:4, pages 398-410.
Crossref
Crossref
Michael D. Shultz, Xueying Cao, Christine H. Chen, Young Shin Cho, Nicole R. Davis, Joe Eckman, Jianmei Fan, Alex Fekete, Brant Firestone, Julie Flynn, Jack Green, Joseph D. Growney, Mats Holmqvist, Meier Hsu, Daniel Jansson, Lei Jiang, Paul Kwon, Gang Liu, Franco Lombardo, Qiang Lu, Dyuti Majumdar, Christopher Meta, Lawrence Perez, Minying Pu, Tim Ramsey, Stacy Remiszewski, Suzanne Skolnik, Martin Traebert, Laszlo Urban, Vinita Uttamsingh, Ping Wang, Steven Whitebread, Lewis Whitehead, Yan Yan-Neale, Yung-Mae Yao, Liping Zhou & Peter Atadja. (2011) Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry 54:13, pages 4752-4772.
Crossref
Crossref